Fig. 1.
HCV replicon elimination assays using a wild-type GT1b and b DCV + ASV-resistant (NS3-D168V, NS5A-L31M-Y93H) replicon cell lines treated with indicated combination regimens at multiple EC50 values for each agent (determined in wild-type replicon). Data for Days 3, 7, and 14 are shown; complete data are shown in Supplementary Fig. 1. ASV asunaprevir, BCV beclabuvir, DCV daclatasvir, GT genotype, HCV hepatitis C virus, LDV ledipasvir, NS3 non-structural protein 3, NS5A non-structural protein 5A, SMV simeprevir, SOF sofosbuvir